10-KPeriod: FY2003

BIOGEN INC. Annual Report, Year Ended Dec 31, 2003

Filed March 10, 2004For Securities:BIIB

Summary

Biogen Idec Inc. (following its merger with IDEC Pharmaceuticals Corporation in November 2003) reported total revenues of $679.2 million for the year ended December 31, 2003. A significant portion of this revenue ($493.0 million) came from the joint business arrangement related to RITUXAN, primarily through copromotion profits in the U.S. and royalties from international sales. The company also generated $171.6 million in product sales, with AVONEX (for Multiple Sclerosis) contributing the majority ($142.6 million) in the period following the merger. ZEVALIN and AMEVIVE contributed $19.6 million and $9.4 million, respectively, in product sales during 2003. The company incurred a net loss of $875.1 million for the year, largely due to an $823 million charge for acquired in-process research and development related to the merger. The company highlights its strong position in oncology and immunology, driven by key products like AVONEX and RITUXAN. The merger created a more diversified entity with a strengthened R&D pipeline. Future growth is expected to be driven by the successful commercialization of existing products and the development of new therapies, including ANTEGREN, a promising candidate for Multiple Sclerosis and Crohn's disease.

Key Highlights

  • 1The company completed a significant merger with IDEC Pharmaceuticals Corporation in November 2003, forming Biogen Idec Inc., which is expected to diversify revenue streams and strengthen the R&D pipeline.
  • 2Total revenues for 2003 reached $679.2 million, with a substantial contribution from the RITUXAN joint business ($493.0 million).
  • 3AVONEX sales were $142.6 million for the partial period following the merger, showcasing its strong performance in the Multiple Sclerosis market.
  • 4ZEVALIN and AMEVIVE generated $19.6 million and $9.4 million in product sales, respectively, indicating early-stage commercial performance.
  • 5A significant net loss of $875.1 million was reported, heavily influenced by an $823 million charge for acquired in-process R&D from the merger.
  • 6The company has a robust pipeline with ANTEGREN showing promise for Multiple Sclerosis and Crohn's disease, with plans for FDA submission in mid-2004.
  • 7The company faces ongoing litigation related to ZEVALIN patent disputes, with a settlement agreement reached in February 2004.

Frequently Asked Questions

For the year ended December 31, 2003, Biogen Idec reported total revenues of $679.2 million, a net loss of $875.1 million, and had $2.3 billion in cash, cash equivalents, and marketable securities. The significant net loss was largely due to an $823 million charge for acquired in-process research and development related to the merger with IDEC Pharmaceuticals Corporation.

The company's key commercial products include AVONEX (Multiple Sclerosis), RITUXAN (B-cell NHLs), ZEVALIN (B-cell NHLs), and AMEVIVE (psoriasis). In 2003, AVONEX sales (for the period post-merger) were $142.6 million. RITUXAN contributed significantly through U.S. copromotion profits ($419.2 million) and international royalties ($67.9 million). ZEVALIN generated $19.6 million in sales, and AMEVIVE generated $9.4 million in sales (for the period post-merger).

The merger, completed in November 2003, created Biogen Idec Inc. It combined complementary strengths in oncology and immunology, aiming to establish new standards of care. The merger provided product portfolio diversification, strengthened R&D capabilities, and expanded the product pipeline, positioning the company for future growth.

Key risks include heavy reliance on a few core products (AVONEX and RITUXAN) for revenue, intense competition in the biotechnology and pharmaceutical industries, potential manufacturing issues, reliance on third-party manufacturers and suppliers, government regulations, and uncertainties surrounding intellectual property rights and patent litigation. The significant charge for in-process R&D also impacted the 2003 financial results.